Streetbeat News

BPTS

Biophytis

https://www.biophytis.com/

CEO

Stanislas Veillet

Employees

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

biophytis is a biotech company developping therapeutics for aging diseases. it that has been created in 2006 as a spin-off of université pierre et marie curie (paris). biophytis has developped a portfolio of drug candidates at clinical stage for the treatment of sarcopenic obesity (bio101, bio103) and dry age-related macular degeneration (bio201).

Open

8.24

Mkt cap

2.6M

Volume

18K

High

8.96

P/E Ratio

-0.06

52-wk high

168.80

Low

8.05

Div yield

N/A

52-wk low

8.05

Biophytis SA, a clinical-stage biotechnology company, will participate in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR) in March 2025. The conference focuses on advancing clinical trials for frail older adults.

Portfolio Pulse from

February 25, 2025 | 6:15 am

Biophytis SA, a clinical-stage biotech company, has unveiled its strategic outlook for 2025, focusing on launching a clinical program for obesity, signing a licensing agreement with Blanver, negotiating with a Chinese pharma company, and co-developing with AskHelpU in ALS.

Portfolio Pulse from

February 11, 2025 | 6:15 am

Biophytis SA, a clinical-stage biotechnology company, will participate in the Biomed Forum on February 4, 2025, in Paris. This event connects biotech and medtech companies with institutional investors.

Portfolio Pulse from

January 27, 2025 | 6:15 am

Biophytis SA has signed a co-development agreement with AskHelpU to evaluate the efficacy of its lead drug candidate, BIO101, in treating ALS in China.

Portfolio Pulse from

January 21, 2025 | 6:15 am

Biophytis SA, a clinical-stage biotech company, is implementing a strategy to find partners for its obesity drug, BIO101, currently in phase 2 development. The company aims to license out BIO101 for co-development and commercialization, targeting the high-prevalence obesity markets in the USA, China, and Brazil. Biophytis will attend the BIO US conference in San Diego to advance this strategy, emphasizing the need for collaboration to address the obesity challenge.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 1:12 pm

Caterpillar Inc. shares fell by 6.6% after missing revenue estimates for Q1 fiscal 2024, despite beating EPS expectations. Other stocks experienced significant movements, with notable gainers including Barfresh Food Group and Safe & Green Holdings, and losers like E-Home Household Service Holdings and Chicken Soup for the Soul Entertainment.

Portfolio Pulse from Avi Kapoor

April 25, 2024 | 5:57 pm

Teradyne, Inc. (NASDAQ:TER) shares surged over 8% in pre-market trading following strong first-quarter results and an optimistic second-quarter forecast. Other stocks also showed significant movement in pre-market trading, with notable gainers including Intelligent Living Application Group Inc. (NASDAQ:ILAG) and losers like Biophytis S.A. (NASDAQ:BPTS).

Portfolio Pulse from Avi Kapoor

April 25, 2024 | 10:12 am

Trading for BPTS was halted and then resumed at 8:55 AM ET, following an update on halt status. The update included news and specific times for the resumption of quotations.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 12:55 pm

Trading for BPTS was halted at 7:50:00 p.m. ET due to pending news. The halt is a temporary measure until the news affecting the company is released.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:50 pm

Biophytis shares are trading lower following the announcement of a change in the ratio of its American Depositary Shares (ADS) from 100 to 4,000.

Portfolio Pulse from Benzinga Newsdesk

April 19, 2024 | 3:28 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.